

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: ZALIPSKY *et al.*

APPLICATION No.: 10/723,473

FILED: November 26, 2003

FOR: RELEASABLE LINKAGE AND
COMPOSITIONS CONTAINING THE SAME

EXAMINER: Riley, J.

ART UNIT: 1637

CONF. No: 7930

**Information Disclosure Statement After First Office Action but
Before Final Action or Notice of Allowance – 37 C.F.R. § 1.97(c)**

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

Copies of the following references are enclosed:

All cited references except U.S. patents and publications (Full copies of references 22 and 24 are provided per Examiners request in Office Action dated 9/15/06)

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))

Applicant elects to pay the fee under 37 C.F.R. § 1.17(p) \$180.00.

A check is enclosed for \$180.00 covering the above fee.

Please charge any underpayment for timely filing of this paper to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: 12.22.06

Judy M
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/723,473
				Confirmation Number	7930
				Filing Date	November 26, 2003
				First Named Inventor	Samuel Zalipsky
				Group Art Unit	1637
				Examiner Name	Riley, J.
				Attorney Docket No.	55325-8167.US02
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document
		NUMBER	Kind Code (if known)		
	1.	4,021,449		Fujimoto <i>et al.</i>	5/77
	2.	6,638,500	B1	El-Tayar Nabil <i>et al.</i>	10/03
	3.	2004/0213579	A1	Zalipsky <i>et al.</i>	10/04

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document
		Office	NUMBER		
	4.	EP	EP 0 317 956	A2/A3	Senter, Peter D.
	5.	EP	EP 0 317 957	B1	Senter, Peter D.
	6.	EP	EP 0 898 968	B1	Maeda <i>et al.</i>
	7.	EP	EP 0 510 197	A1	Seki <i>et al.</i>
	8.	FR	2 254 336		Kyowa Hakko Kogyo
	9.	JP	1113391		Saito <i>et al.</i>
	10.	PCT	WO 97/36904		Sagami Chem Res.
	11.	PCT	WO 99/29302		Edwards <i>et al.</i>
	12.	PCT	WO 00/64484	A2/A3	Alza Corporation
	13.	PCT	WO00/64483	A2/A3	Alza Corporation
	14.	PCT	WO01/26629	A2/A3	Alza Corporation
	15.	PCT	WO02/26265	A2/A3	Schering Corporation
	16.	PCT	WO03/053409		Alza Corporation
	17.	PCT	WO04/110497	A2/A3	Alza Corporation

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.				T
	18.	Asai <i>et al.</i> , Biol. Pharm. Bull., 21(7):766-771 (1998).				
	19.	Briddell <i>et al.</i> , Blood, 102(11):163b-164b, Abstract #4364 (1999).				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/723,473
				Confirmation Number	7930
				Filing Date	November 26, 2003
				First Named Inventor	Samuel Zalipsky
				Group Art Unit	1637
				Examiner Name	Riley, J.
Sheet	2	of	2	Attorney Docket No.	55325-8167.US02

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	20.	Database Dissertation Abstracts [Online] Proquest Info & Learning; Woghiren, Clement O. et al.: "Synthesis, Characterization and Conjugation of a Novel Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification (IL-2)" Dialog Accession No. 01367093; Dissertation Abstracts 55(03-B), 1994, page 866		
	21.	Diaz et al., Bioconjugate Chemistry, 9:250-254 (1998).		
	22.	Ellman, G.I., Arch. Biochem. Biophys., 82:70-77 (1959).		
	23.	Engman et al., Bioorganic & Medical Chemistry, 11:5091-5100 (2003).		
	24.	Grassetti and Murray, Arch. Biochem. Biophys., 119(1):41-49 (1967).		
	25.	Johnson et al., Chemistry and Biology, 4(12):939-950 (1997).		
	26.	Malik et al., Experimental Hematology, 28(7, Suppl. 1):page 106, Abstract No. 237 (2000).		
	27.	Zalipsky et al., Bioconjugate Chem., 10(5):703-707 (1999).		
	28.	Zalipsky, S., et al., 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, Publisher: Controlled Release Society 1:437-438, (2001).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	